Biopharma AI
ByCan Johnson & Johnson’s $350 Million AI Investment in 2025 Transform Drug Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Johnson & Johnson significantly expanded its use of artificial intelligence (AI) across…
AbbVie Invested $400 Million in AI in 2025: How This Will Transform Discovery, R&D, and Commercialization in 2026
Global – December 31, 2025 — AbbVie Inc. significantly expanded the integration of artificial intelligence (AI) and data-driven…
Is Eli Lilly’s $450 Million AI Investment in 2025 Set to Transform Drug Discovery, R&D, and Commercialization?
Global – December 31, 2025 — Eli Lilly and Company significantly expanded its artificial intelligence (AI) investments in…
Is Pfizer’s $500 Million AI Investment in 2025 Poised to Redefine Drug Discovery and Commercialization?
Global – December 31, 2025 — Pfizer Inc. significantly increased investment in artificial intelligence (AI) across its discovery,…
Can ReviR’s AI-Powered RNA Modulation Platform Convert $50M+ in Funding into Scalable Genetic Medicines?
Executive Summary ReviR Therapeutics continues to establish itself as a leader in RNA-targeting small molecule drug discovery, advancing…
Can Ainnocence’s Causal AI Platform Redefine Drug Discovery Value as Pharma Expands AI Partnerships?
Strategic Overview Ainnocence is carving out a differentiated role in AI-driven drug discovery by emphasizing causal, mechanism-oriented artificial…
